Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.

Berton, Mattia; Bettonte, Sara; Stader, Felix; Battegay, Manuel; Marzolini, Catia

Berton, Mattia; Bettonte, Sara; Stader, Felix; Battegay, Manuel; Marzolini, Catia.

Affiliation

Berton M; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
Bettonte S; Faculty of Medicine, University of Basel, Basel, Switzerland.
Stader F; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
Battegay M; Faculty of Medicine, University of Basel, Basel, Switzerland.
Marzolini C; Certara UK Limited, Sheffield, UK.

Open Forum Infect Dis ; 10(7): ofad361, 2023 Jul.

Article de En | MEDLINE | ID: mdl-37496606

Mots clés

PBPK modeling; dolutegravir; drugdrug interaction; obesity; rifampicin

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Prognostic_studies Langue: En Journal: Open Forum Infect Dis Année: 2023 Type de document: Article Pays d'affiliation: Suisse Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google